PMID- 25568448
OWN - NLM
STAT- MEDLINE
DCOM- 20150909
LR  - 20181113
IS  - 1477-9145 (Electronic)
IS  - 0022-0949 (Print)
IS  - 0022-0949 (Linking)
VI  - 218
IP  - Pt 1
DP  - 2015 Jan 1
TI  - Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in 
      depression and response to antidepressants.
PG  - 21-31
LID - 10.1242/jeb.107086 [doi]
AB  - Major depressive disorder (MDD) is a devastating neuropsychiatric disorder 
      encompassing a wide range of cognitive and emotional dysfunctions. The prevalence 
      of MDD is expected to continue its growth to become the second leading cause of 
      disease burden (after HIV) by 2030. Despite an extensive research effort, the 
      exact etiology of MDD remains elusive and the diagnostics uncertain. Moreover, a 
      marked inter-individual variability is observed in the vulnerability to develop 
      depression, as well as in response to antidepressant treatment, for nearly 50% of 
      patients. Although a genetic component accounts for some cases of MDD, it is now 
      clearly established that MDD results from strong gene and environment 
      interactions. Such interactions could be mediated by epigenetic mechanisms, 
      defined as chromatin and DNA modifications that alter gene expression without 
      changing the DNA structure itself. Some epigenetic mechanisms have recently 
      emerged as particularly relevant molecular substrates, promoting vulnerability or 
      resilience to the development of depressive-like symptoms. Although the role of 
      brain-derived neurotrophic factor (BDNF) in the pathophysiology of MDD remains 
      unclear, its modulation of the efficacy of antidepressants is clearly 
      established. Therefore, in this review, we focus on the epigenetic mechanisms 
      regulating the expression of BDNF in humans and in animal models of depression, 
      and discuss their role in individual differences in vulnerability to depression 
      and response to antidepressant drugs.
CI  - (c) 2015. Published by The Company of Biologists Ltd.
FAU - Duclot, Florian
AU  - Duclot F
AD  - Department of Biomedical Sciences, Neuroscience Program, Florida State 
      University, Tallahassee, FL 32306, USA.
FAU - Kabbaj, Mohamed
AU  - Kabbaj M
AD  - Department of Biomedical Sciences, Neuroscience Program, Florida State 
      University, Tallahassee, FL 32306, USA mohamed.kabbaj@med.fsu.edu.
LA  - eng
GR  - R01 MH087583/MH/NIMH NIH HHS/United States
GR  - R01 MH099085/MH/NIMH NIH HHS/United States
GR  - R21 MH081046/MH/NIMH NIH HHS/United States
GR  - R21 MH083128/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - J Exp Biol
JT  - The Journal of experimental biology
JID - 0243705
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/pharmacology/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Depression/*drug therapy/*genetics
MH  - Disease Models, Animal
MH  - *Epigenesis, Genetic/drug effects
MH  - Genetic Predisposition to Disease
MH  - Humans
PMC - PMC4286703
OTO - NOTNLM
OT  - BDNF
OT  - Epigenetics
OT  - Individual differences
EDAT- 2015/01/09 06:00
MHDA- 2015/09/10 06:00
PMCR- 2016/01/01
CRDT- 2015/01/09 06:00
PHST- 2015/01/09 06:00 [entrez]
PHST- 2015/01/09 06:00 [pubmed]
PHST- 2015/09/10 06:00 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - 218/1/21 [pii]
AID - 10.1242/jeb.107086 [doi]
PST - ppublish
SO  - J Exp Biol. 2015 Jan 1;218(Pt 1):21-31. doi: 10.1242/jeb.107086.